Jonathan Wolleben
Stock Analyst at JMP Securities
(3.83)
# 736
Out of 4,732 analysts
180
Total ratings
43.26%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Reiterates: Market Outperform | $427 | $293.64 | +45.42% | 11 | Jan 10, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $10 | $4.47 | +123.96% | 12 | Jan 10, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Market Outperform | $75 | $54.54 | +37.51% | 2 | Dec 23, 2024 | |
| SVRA Savara | Reiterates: Market Outperform | $9 | $2.93 | +207.17% | 8 | Dec 19, 2024 | |
| HGV Hilton Grand Vacations | Maintains: Market Outperform | $55 → $50 | $40.41 | +23.73% | 1 | Dec 18, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Market Outperform | $91 | $27.06 | +236.29% | 7 | Dec 18, 2024 | |
| CSGP CoStar Group | Reiterates: Market Outperform | $90 | $73.85 | +21.87% | 1 | Dec 16, 2024 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Market Outperform | $87 | $37.35 | +132.93% | 13 | Dec 16, 2024 | |
| ABNB Airbnb | Reiterates: Market Perform | n/a | $135.12 | - | 1 | Dec 16, 2024 | |
| PRQR ProQR Therapeutics | Reiterates: Market Outperform | $8 | $2.37 | +237.55% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.36 | +722.37% | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $485.53 | -0.11% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $3 | $0.86 | +250.67% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $19 → $23 | $7.77 | +196.01% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $15 | $2.66 | +463.91% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $4.39 | +628.93% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $45 → $43 | $36.82 | +16.78% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $16 | $7.45 | +114.77% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $66 → $68 | $46.95 | +44.83% | 8 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $3.34 | +648.50% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $24 | $6.86 | +249.85% | 10 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $22 | $8.01 | +174.66% | 16 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.88 | +814.08% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $49 → $50 | $18.36 | +172.33% | 9 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.93 | +437.69% | 9 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $30.24 | -20.63% | 1 | May 12, 2023 |
Madrigal Pharmaceuticals
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $427
Current: $293.64
Upside: +45.42%
DBV Technologies
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $4.47
Upside: +123.96%
Rhythm Pharmaceuticals
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $75
Current: $54.54
Upside: +37.51%
Savara
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.93
Upside: +207.17%
Hilton Grand Vacations
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $40.41
Upside: +23.73%
Structure Therapeutics
Dec 18, 2024
Reiterates: Market Outperform
Price Target: $91
Current: $27.06
Upside: +236.29%
CoStar Group
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $73.85
Upside: +21.87%
Crinetics Pharmaceuticals
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $87
Current: $37.35
Upside: +132.93%
Airbnb
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $135.12
Upside: -
ProQR Therapeutics
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $2.37
Upside: +237.55%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $3
Current: $0.36
Upside: +722.37%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $485.53
Upside: -0.11%
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $0.86
Upside: +250.67%
Sep 13, 2024
Maintains: Market Outperform
Price Target: $19 → $23
Current: $7.77
Upside: +196.01%
Sep 10, 2024
Initiates: Market Outperform
Price Target: $15
Current: $2.66
Upside: +463.91%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $4.39
Upside: +628.93%
Aug 7, 2024
Maintains: Market Outperform
Price Target: $45 → $43
Current: $36.82
Upside: +16.78%
Aug 6, 2024
Maintains: Market Outperform
Price Target: $15 → $16
Current: $7.45
Upside: +114.77%
Jun 18, 2024
Maintains: Market Outperform
Price Target: $66 → $68
Current: $46.95
Upside: +44.83%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $3.34
Upside: +648.50%
May 10, 2024
Maintains: Market Outperform
Price Target: $25 → $24
Current: $6.86
Upside: +249.85%
May 8, 2024
Maintains: Market Outperform
Price Target: $24 → $22
Current: $8.01
Upside: +174.66%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.88
Upside: +814.08%
Apr 11, 2024
Maintains: Market Outperform
Price Target: $49 → $50
Current: $18.36
Upside: +172.33%
Mar 13, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.93
Upside: +437.69%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $30.24
Upside: -20.63%